Browse > Article
http://dx.doi.org/10.5483/BMBRep.2016.49.4.004

Biphasic activation of extracellular signal-regulated kinase (ERK) 1/2 in epidermal growth factor (EGF)-stimulated SW480 colorectal cancer cells  

Joo, Donghyun (Department of Agricultural Biotechnology and Center for Agricultural Biomaterials)
Woo, Jong Soo (Department of Agricultural Biotechnology and Center for Agricultural Biomaterials)
Cho, Kwang-Hyun (Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology (KAIST))
Han, Seung Hyun (Department of Oral Microbiology and Immunology, Dental Research Institute, and BK21 Program, School of Dentistry, Seoul National University)
Min, Tae Sun (National Research Foundation of Korea)
Yang, Deok-Chun (Korean Ginseng Center and Ginseng Genetic Resource Bank, Kyung Hee University)
Yun, Cheol-Heui (Department of Agricultural Biotechnology and Center for Agricultural Biomaterials)
Publication Information
BMB Reports / v.49, no.4, 2016 , pp. 220-225 More about this Journal
Abstract
Cancer cells have different characteristics due to the genetic differences where these unique features may strongly influence the effectiveness of therapeutic interventions. Here, we show that the spontaneous reactivation of extracellular signalregulated kinase (ERK), distinct from conventional ERK activation, represents a potent mechanism for cancer cell survival. We studied ERK1/2 activation in vitro in SW480 colorectal cancer cells. Although ERK signaling tends to be transiently activated, we observed the delayed reactivation of ERK1/2 in epidermal growth factor (EGF)-stimulated SW480 cells. This effect was observed even after EGF withdrawal. While phosphorylated ERK1/2 translocated into the nucleus following its primary activation, it remained in the cytoplasm during late-phase activation. The inhibition of primary ERK1/2 activation or protein trafficking, blocked reactivation and concurrently increased caspase 3 activity. Our results suggest that the biphasic activation of ERK1/2 plays a role in cancer cell survival; thus, regulation of ERK1/2 activation may improve the efficacy of cancer therapies that target ERK signaling.
Keywords
Biphasic activation; Cancer cell survival; ERK pathway; pERK translocation; SW480 cells;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Yang SH, Sharrocks AD and Whitmarsh AJ (2003) Transcriptional regulation by the MAP kinase signaling cascades. Gene 320, 3-21   DOI
2 Chuderland D, Konson A and Seger R (2008) Identification and characterization of a general nuclear translocation signal in signaling proteins. Mol Cell 31, 850-861   DOI
3 Zeldich E, Koren R, Nemcovsky C and Weinreb M (2007) Enamel matrix derivative stimulates human gingival fibroblast proliferation via ERK. J Dent Res 86, 41-46   DOI
4 Huang Z, Cheng SL and Slatopolsky E (2001) Sustained activation of the extracellular signal-regulated kinase pathway is required for extracellular calcium stimulation of human osteoblast proliferation. J Biol Chem 276, 21351-21358   DOI
5 Nakayama K, Satoh T, Igari A, Kageyama R and Nishida E (2008) FGF induces oscillations of Hes1 expression and Ras/ERK activation. Curr Biol 18, R332-334   DOI
6 Sastre AP, Grossmann S, Reusch HP and Schaefer M (2008) Requirement of an intermediate gene expression for biphasic ERK1/2 activation in thrombin-stimulated vascular smooth muscle cells. J Biol Chem 283, 25871-25878   DOI
7 Sancho E, Batlle E and Clevers H (2004) Signaling pathways in intestinal development and cancer. Annu Rev Cell Dev Biol 20, 695-723   DOI
8 Roberts PJ and Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26, 3291-3310   DOI
9 Lefloch R, Pouyssegur J and Lenormand P (2008) Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels. Mol Cell Biol 28, 511-527   DOI
10 Traverse S, Gomez N, Paterson H, Marshall C and Cohen P (1992) Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor. Biochem J 288 (Pt 2), 351-355   DOI
11 Sparmann A and Bar-Sagi D (2004) Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6, 447-458   DOI
12 Skarpen E, Flinder LI, Rosseland CM et al (2008) MEK1 and MEK2 regulate distinct functions by sorting ERK2 to different intracellular compartments. FASEB J 22, 466-476   DOI
13 Franke TF, Hornik CP, Segev L, Shostak GA and Sugimoto C (2003) PI3K/Akt and apoptosis: size matters. Oncogene 22, 8983-8998   DOI
14 Murphy LO, Smith S, Chen RH, Fingar DC and Blenis J (2002) Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol 4, 556-564
15 Jones SM and Kazlauskas A (2001) Growth-factor-dependent mitogenesis requires two distinct phases of signalling. Nat Cell Biol 3, 165-172   DOI
16 Casar B, Pinto A and Crespo P (2008) Essential role of ERK dimers in the activation of cytoplasmic but not nuclear substrates by ERK-scaffold complexes. Mol Cell 31, 708-721   DOI
17 Cheng C, Yaffe MB and Sharp PA (2006) A positive feedback loop couples Ras activation and CD44 alternative splicing. Genes Dev 20, 1715-1720   DOI
18 Monick M, Staber J, Thomas K and Hunninghake G (2001) Respiratory syncytial virus infection results in activation of multiple protein kinase C isoforms leading to activation of mitogen-activated protein kinase. J Immunol 166, 2681-2687   DOI
19 Volmat V, Camps M, Arkinstall S, Pouyssegur J and Lenormand P (2001) The nucleus, a site for signal termination by sequestration and inactivation of p42/p44 MAP kinases. J Cell Sci 114, 3433-3443
20 Sorkin A and von Zastrow M (2009) Endocytosis and signalling: intertwining molecular networks. Nat Rev Mol Cell Biol 10, 609-622   DOI
21 Grammer TC and Blenis J (1997) Evidence for MEKindependent pathways regulating the prolonged activation of the ERK-MAP kinases. Oncogene 14, 1635-1642   DOI
22 Balciunaite E, Jones S, Toker A and Kazlauskas A (2000) PDGF initiates two distinct phases of protein kinase C activity that make unequal contributions to the G0 to S transition. Curr Biol 10, 261-267   DOI
23 Jones SM, Klinghoffer R, Prestwich GD, Toker A and Kazlauskas A (1999) PDGF induces an early and a late wave of PI 3-kinase activity, and only the late wave is required for progression through G1. Curr Biol 9, 512-521   DOI
24 Nakanishi M and Rosenberg DW (2006) Roles of cPLA2alpha and arachidonic acid in cancer. Biochim Biophys Acta 1761, 1335-1343   DOI
25 Soydan AS, Tavares IA, Weech PK, Temblay NM and Bennett A (1996) High molecular weight phospholipase A2 and fatty acids in human colon tumours and associated normal tissue. Eur J Cancer 32A, 1781-1787   DOI
26 Ballif BA and Blenis J (2001) Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ 12, 397-408
27 Sharma SV and Settleman J (2007) Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 21, 3214-3231   DOI
28 Fang JY and Richardson BC (2005) The MAPK signalling pathways and colorectal cancer. Lancet Oncol 6, 322-327   DOI